Antagonism effect of nicotine on Aβ 25-35 cytotoxicity and its relation with the metabolism of β-amyloid precursor protein

Chinese Journal of Contemporary Neurology and Neurosurgery

Volumn 7, Issue 3, 2007, Pages 251-256

  Ren, Ru Jing ^a   Wang, Gang ^a   Pan, Jing ^a   Yang, Hong Qi ^a   Lu, Guo Qiang ^a   Chen, Sheng Di ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer disease; Amyloid beta protein; Amyloid beta protein precursor; Nicotine

Indexed keywords

EID: 84861487687     PISSN: 16726731     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Oddo S, LaFerla FM. The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris, 2006, 99: 172-179.
2. Zanardi A, Leo G, Biagini G, et al. Nicotine and neurodegeneration in ageing. Toxicol Lett, 2002, 127: 207-215.
3. Sabbagh MN, Lukas RJ, Sparks DL, et al. The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. J Alzheimers Dis, 2002, 4: 317-325.
4. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev, 2001, 81: 741-766.
5. Stein TD, Anders NJ, DeCarli C, et al. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci, 2004, 24: 7707-7717.
6. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord, 2006, 20(2 Suppl 1): 12-18.
7. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci, 1997, 20: 154-159.
8. Yamamoto K, Miyoshi T, Yae T, et al. The survival of rat cerebral cortical neurons in the presence of trophic APP peptides. J Neurobiol, 1994, 25: 585-594.
9. Lenzken SC, Lanni C, Govoni S, et al. Nicotinic component of galan-tamine in the regulation of amyloid precursor protein processing. Chem Biol Interact, 2007, 165: 138-145.
10. Lahiri DK, Farlow MR, Hintz N, et al. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand Suppl, 2000, 176: 60-67.
11. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res, 1994, 37: 777-787.
12. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging, 2006, 27: 190-198.
13. Farris W, Mansourian S, Leissring MA, et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol, 2004, 164: 1425-1434.
14. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA, 2003, 100: 4162-4167.
15. Edbauer D, Willem M, Lammich S, et al. Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J Biol Chem, 2002, 277: 13389-13393.